Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration

Overview

This study aimed to explore the pharmacokinetics and pharmacodynamics of low dose sertraline with [11C] sertraline positron emission tomography (PET) study.

Full Title of Study: “[11C] Sertraline PET Imaging Study That Investigates Pharmacokinetics and Pharmacodynamics of Sertraline After Low Dose Administration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2009

Detailed Description

Open, one arm, single sequence, 3-period, dose escalating study for healthy volunteers are investigated. Ten subjects may be enrolled. Subjects receive baseline [11C] sertraline PET. Period 1 Subjects receive 5 mg of sertraline every day. After 6 day of medication, pharmacokinetic and PET studies are performed. Period 2 Subjects receive 25 mg of sertraline every day. After 6 day of medication, pharmacokinetic and PET studies are performed. Period 3 Subjects receive 50 mg of sertraline every day. After 6 day of medication, pharmacokinetic and PET studies are performed.

Interventions

  • Drug: Sertraline
    • Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.

Arms, Groups and Cohorts

  • Experimental: Sertraline
    • Single Arm

Clinical Trial Outcome Measures

Primary Measures

  • Serotonin receptor occupancy
    • Time Frame: Day -1, Day 7, Day 14, Day 21

Secondary Measures

  • Plasma concentration of sertraline
    • Time Frame: Day 4, 5, 6, 7, 11, 12, 13, 14, 18, 19, 20, 21

Participating in This Clinical Trial

Inclusion Criteria

  • Age: Between 20 to 50 years of age, inclusive (age based on the date to give the informed consent) – Weight: Over 55 kg, within ±20% of ideal body weight – Subject who are reliable and willing to make themselves available during the study period, are willing to follow the study protocol, and give their written informed consent voluntarily Exclusion Criteria:

  • History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease – History of a significant surgical resection of gastrointestinal tract except appendectomy – Abnormal clinical laboratory findings, especially for AST or ALT > 1.25 fold of upper normal limit – Subject who has phobia for PET scan – History or evidence of drug abuse – Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (If used medication is considered acceptable by investigator, patients can be included) – Participation in clinical trials of any drug within 2 months prior to the participation of the study – Donation of whole blood within 2 months or a unit of blood within 1 month prior to the start of study – Judged to be inappropriate for the study by the investigator

Gender Eligibility: Male

Minimum Age: 20 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Seoul National University Hospital
  • Collaborator
    • Ministry of Health, Welfare and Family Affairs
  • Provider of Information About this Clinical Study
    • Kyung-Sang Yu/Professor, Seoul National University Hospital
  • Overall Official(s)
    • Kyung-Sang Yu, MD, PhD, Principal Investigator, Seoul National University College of Medicine and Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.